{"id":"ravulizumab-cwvz","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Upper respiratory tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypertension","drugRate":"","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary tract infection","drugRate":"","severity":"common","organSystem":""},{"effect":"COVID-19","drugRate":"","severity":"common","organSystem":""},{"effect":"Anemia","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Infusion-related reactions","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Viral tonsilitis","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Meningococcal infectious disease"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hypertension","drugRate":"2.7%","severity":"serious"},{"effect":"Pneumonia","drugRate":"2.7%","severity":"serious"},{"effect":"Abdominal pain","drugRate":"2.7%","severity":"serious"},{"effect":"Sepsis","drugRate":"","severity":"serious"},{"effect":"Intracranial hemorrhage","drugRate":"","severity":"serious"},{"effect":"Cerebral arterial thrombosis","drugRate":"","severity":"serious"},{"effect":"Hyperthermia","drugRate":"","severity":"serious"},{"effect":"Pyrexia","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT05288673","NCT04248465","NCT04999020","NCT05116774","NCT04390464","NCT05131204","NCT03056040","NCT05288660","NCT04201262","NCT05982938","NCT05288829","NCT07399730","NCT01374360","NCT04543591","NCT04564339","NCT04743804","NCT05288816","NCT05274633","NCT06333652","NCT06312644","NCT05346354","NCT04202341","NCT04320602","NCT02949128","NCT03920293","NCT07413250","NCT03406507","NCT03131219","NCT02605993","NCT04557735","NCT05396742","NCT06909253","NCT05133531","NCT04369469"],"aliases":[],"company":"ALEXION PHARM","patents":[],"pricing":[],"allNames":"ultomiris","offLabel":[],"timeline":[],"brandName":"ULTOMIRIS","ecosystem":[],"mechanism":{"target":"Complement C5","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"RAVULIZUMAB-CWVZ","indications":{"approved":[{"name":"Atypical hemolytic uremic syndrome (aHUS)","diseaseId":"atypical-hemolytic-uremic-syndrome-(ahus)","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Generalized myasthenia gravis","diseaseId":"generalized-myasthenia-gravis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myasthenia gravis","diseaseId":"myasthenia-gravis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Paroxysmal nocturnal hemoglobinuria","diseaseId":"paroxysmal-nocturnal-hemoglobinuria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"ALEXION PHARM","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05288673","phase":"Phase 1","title":"A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered ","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2016-09-01"},{"nctId":"NCT04248465","phase":"Phase 3","title":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic ","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":382,"indication":"Amyotrophic Lateral Sclerosis, ALS","completionDate":"2021-10-17"},{"nctId":"NCT04999020","phase":"Phase 2","title":"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":38,"indication":"Dermatomyositis","completionDate":"2024-05-08"},{"nctId":"NCT05116774","phase":"Phase 2","title":"A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in S","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","isPivotal":false,"enrollment":12,"indication":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","completionDate":"2023-09-14"},{"nctId":"NCT04390464","phase":"Phase 4","title":"mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","isPivotal":false,"enrollment":1167,"indication":"COVID19","completionDate":"2022-05-01"},{"nctId":"NCT05131204","phase":"Phase 3","title":"A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglob","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"enrollment":3,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2023-07-12"},{"nctId":"NCT03056040","phase":"Phase 3","title":"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":202,"indication":"Paroxysmal Nocturnal Hemoglobinuria (PNH)","completionDate":"2022-02-21"},{"nctId":"NCT05288660","phase":"Phase 1","title":"A Phase 1, Randomized, Blinded, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALXN1210 Administered I","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":14,"indication":"Healthy","completionDate":"2015-03-13"},{"nctId":"NCT04201262","phase":"Phase 3","title":"A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":58,"indication":"Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder","completionDate":"2024-10-31"},{"nctId":"NCT05982938","phase":"N/A","title":"Early Access Program (EAP) for Danicopan as Add-on Treatment to SOLIRIS® or ULTOMIRIS® in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Clinically Significant Extravascular Hemolysi","status":"AVAILABLE","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":0,"indication":"Paroxysmal Nocturnal Hemoglobinuria, PNH","completionDate":""},{"nctId":"NCT05288829","phase":"Phase 1","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of a Single Dose of ALXN1210 Administered Subcutaneously Compared to Intravenously in Healt","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":42,"indication":"Healthy","completionDate":"2017-07-18"},{"nctId":"NCT07399730","phase":"N/A","title":"A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","isPivotal":false,"enrollment":80,"indication":"Atypical Hemolytic Uremic Syndrome","completionDate":"2030-12-31"},{"nctId":"NCT01374360","phase":"N/A","title":"Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":6061,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2025-04-14"},{"nctId":"NCT04543591","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell T","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":148,"indication":"Thrombotic Microangiopathy","completionDate":"2026-03-20"},{"nctId":"NCT04564339","phase":"Phase 2","title":"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephr","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":123,"indication":"Lupus Nephritis, Immunoglobulin A Nephropathy","completionDate":"2025-08-18"},{"nctId":"NCT04743804","phase":"Phase 3","title":"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With ","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":16,"indication":"Thrombotic Microangiopathy","completionDate":"2022-12-22"},{"nctId":"NCT05288816","phase":"Phase 1","title":"A Phase 1, Open-Label, Single Ascending and Multiple Set Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously ","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2017-07-05"},{"nctId":"NCT05274633","phase":"N/A","title":"Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study.","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":120,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2025-03-24"},{"nctId":"NCT06333652","phase":"Phase 2","title":"Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders","status":"RECRUITING","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":14,"indication":"Preeclampsia","completionDate":"2028-12-31"},{"nctId":"NCT06312644","phase":"N/A","title":"Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":75,"indication":"Ultomiris-exposed Pregnant/ Postpartum, Pregnancy","completionDate":"2034-07-11"},{"nctId":"NCT05346354","phase":"Phase 2","title":"A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With A","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":12,"indication":"Neuromyelitis Optica Spectrum Disorder","completionDate":"2029-04-02"},{"nctId":"NCT04202341","phase":"N/A","title":"Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":500,"indication":"Generalized Myasthenia Gravis","completionDate":"2029-10-01"},{"nctId":"NCT04320602","phase":"Phase 4","title":"Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":18,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2022-12-20"},{"nctId":"NCT02949128","phase":"Phase 3","title":"Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":58,"indication":"Atypical Hemolytic Uremic Syndrome (aHUS)","completionDate":"2023-01-24"},{"nctId":"NCT03920293","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia G","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":175,"indication":"Generalized Myasthenia Gravis","completionDate":"2023-05-25"},{"nctId":"NCT07413250","phase":"N/A","title":"A Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of International PNH Interest Group (IPIG)-Registry Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":50,"indication":"Paroxysmal Nocturnal Hemoglobinuria, PNH","completionDate":"2030-01-15"},{"nctId":"NCT03406507","phase":"Phase 3","title":"A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":13,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2022-08-25"},{"nctId":"NCT03131219","phase":"Phase 3","title":"A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":34,"indication":"Atypical Hemolytic Uremic Syndrome (aHUS)","completionDate":"2022-12-20"},{"nctId":"NCT02605993","phase":"Phase 2","title":"A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Pa","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":26,"indication":"Paroxysmal Nocturnal Hemoglobinuria, PNH","completionDate":"2022-01-12"},{"nctId":"NCT04557735","phase":"Phase 3","title":"A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Tr","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":41,"indication":"Thrombotic Microangiopathy","completionDate":"2025-05-27"},{"nctId":"NCT05396742","phase":"Phase 1","title":"A Partially Randomized, Sequential Cohort, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous Ravulizumab Coadminist","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":false,"enrollment":49,"indication":"Healthy","completionDate":"2019-05-21"},{"nctId":"NCT06909253","phase":"N/A","title":"Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).","status":"RECRUITING","sponsor":"AstraZeneca","isPivotal":false,"enrollment":50,"indication":"Myasthenia Gravis, Generalized","completionDate":"2029-12-31"},{"nctId":"NCT05133531","phase":"Phase 3","title":"A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","isPivotal":true,"enrollment":190,"indication":"Paroxysmal Nocturnal Hemoglobinuria","completionDate":"2027-01-28"},{"nctId":"NCT04369469","phase":"Phase 3","title":"A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pne","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","isPivotal":true,"enrollment":202,"indication":"COVID-19 Severe Pneumonia, Acute Lung Injury","completionDate":"2021-04-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"INJECTION","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"ALEXION PHARM","companyId":"alexion-pharm","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"ULTOMIRIS, also known as ravulizumab, is a medication used to treat conditions such as Paroxysmal Nocturnal Hemoglobinuria, COVID-19 severe pneumonia, and Acute Lung Injury, as well as Generalized Myasthenia Gravis. It works by inhibiting the complement system, a part of the immune system, as indicated by its listing in ChEMBL.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}